Rivals turn partners for COVID-19 vaccine challenge
Fierce rivals normally, the COVID-19 crisis has led pharmaceutical companies to join forces to work together to produce the billions of vaccines needed globally.
Mar 3, 2021
0
1
Fierce rivals normally, the COVID-19 crisis has led pharmaceutical companies to join forces to work together to produce the billions of vaccines needed globally.
Mar 3, 2021
0
1
French drugmaker Sanofi has made another big purchase aimed at strengthening its position in rare disease treatments, buying Belgian biotech company Ablynx for 3.9 billion euros ($4.8 billion).
Jan 29, 2018
0
4
A French pharmaceutical company developing a Zika vaccine funded with millions of dollars in research grants from the U.S. government has rejected a request from the U.S. Army to set an affordable price for the drug once ...
Jun 14, 2017
0
2
The World Health Organization says it's worried that millions of doses of polio vaccine might be wasted in Ukraine after a patient group raised concerns that the doses are unsafe.
Oct 8, 2015
0
9
The Philippines said Thursday that some of the 14 children who died after receiving a controversial vaccine showed signs of "severe dengue", as investigators probe the drug whose use was suspended due to health concerns.
Jan 11, 2018
0
1
The World Health Organization says the first-ever vaccine for dengue needs to be dealt with in "a much safer way," meaning that the shot should mostly be given to people who have previously been infected with the disease.
Apr 19, 2018
0
0
Dutch authorities said Tuesday they have recalled 11 tonnes of horsemeat that was trafficked from France last year.
Jan 14, 2014
0
0
US cancer drugmaker Medivation said Tuesday it agreed to share confidential data with Sanofi after rejecting a second, higher offer from the French company.
Jul 6, 2016
0
0
Drugmaker Sanofi is abandoning two drugs in the late stages of development after trials revealed they weren't more effective than other therapies.
Jun 3, 2013
0
0
French pharmaceutical group Sanofi reported a slump in profits for the third quarter of the year on Wednesday owing to the lagging effects of the ending of exclusive patent rights.
Oct 30, 2013
0
0